Julian Chandler
Associate Director Alexion, AstraZeneca Rare Disease
Seminars
Thursday 31st July 2025
Discovery of a Novel Trifunctional Inhibitor for B Cell Driven Diseases
11:00 am
• Trifunctional target inhibition to address the root causes of B cell-driven diseases
• Engineering best-in-class pH-dependent binding to FcRn for clearance of IgG and extended 1/2-life
